+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
IL-23 Receptor Antagonist Market - Global Forecast 2026-2032- Product Image
IL-23 Receptor Antagonist Market - Global Forecast 2026-2032- Product Image
Sale

IL-23 Receptor Antagonist Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6139308
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The IL-23 Receptor Antagonist Market is projected to reach USD 22.74 Billion in 2026. It is expected to continue growing at a CAGR of 7.90%, reaching USD 36.00 Billion by 2032.

IL-23 Receptor Antagonists: Executive Overview

IL-23 receptor antagonists represent a targeted therapeutic approach intended to interrupt signaling involved in chronic immune-mediated inflammation. Their relevance is shaped by advances in disease biology, increasing use of pathway-directed treatment strategies, and the need to balance durable disease control with safety, administration convenience, and patient selection. Clinical interpretation should remain indication-specific because efficacy, treatment positioning, and regulatory status can differ across diseases and jurisdictions.

Therapeutic Strategy Is Shifting Toward Durable, Targeted Control

The landscape is moving from broad immunosuppression toward therapies that selectively modulate validated inflammatory pathways. This shift places greater emphasis on long-term disease control, treatment persistence, prevention of structural or functional damage, and practical delivery options. Evidence standards are also becoming more demanding, with stakeholders evaluating comparative effectiveness, quality-of-life outcomes, safety monitoring, and performance in patients who have previously received other biologic or targeted therapies.

Artificial Intelligence Strengthens Discovery, Development, and Care Pathways

Artificial intelligence can support IL-23 receptor antagonist development by integrating multi-omic data, identifying biologically meaningful patient subgroups, prioritizing translational hypotheses, and improving trial recruitment. In clinical practice, algorithmic tools may help organize longitudinal records, detect response patterns, and support monitoring for treatment-related risks. These applications require clinically representative data, transparent validation, privacy safeguards, and human oversight; AI should complement rather than replace physician judgment or prospective evidence.

Regional Insights: Access and Evidence Requirements Differ Across Markets

North America combines advanced specialty-care infrastructure with demanding evidence and payer requirements. Europe emphasizes health-technology assessment, coordinated regulatory processes, and budget-impact considerations, while country-level access can vary. Asia-Pacific presents diverse regulatory systems, growing specialist capacity, and differing reimbursement pathways. Latin America is influenced by public-sector procurement, affordability, and uneven specialist access. The Middle East is developing advanced clinical capabilities alongside concentrated referral networks, and Africa faces broader constraints in diagnostics, biologic availability, cold-chain logistics, and continuity of specialist care.

Group Insights: Policy Alignment Shapes Adoption Conditions

ASEAN markets require attention to regulatory diversity, cross-border supply considerations, and uneven access to specialist services. BRICS economies combine substantial clinical needs with varied domestic manufacturing, reimbursement, and evidence expectations. The European Union benefits from shared regulatory structures but retains national differences in health-technology assessment and funding. G7 systems generally emphasize rigorous comparative evidence, pharmacovigilance, and value assessment. GCC countries often have centralized purchasing and advanced urban healthcare hubs, while NATO members span highly varied health systems and procurement models, making alliance membership an imperfect proxy for treatment access.

Country Insights: National Systems Create Distinct Priorities

Australia emphasizes national reimbursement assessment and specialist prescribing within a geographically dispersed system. Brazil combines public and private delivery channels, with access shaped by procurement and regional disparities. Canada’s provincial funding structures can produce differing pathways. China is influenced by regulatory modernization, hospital access, and negotiated reimbursement. France, Germany, Italy, Spain, and the United Kingdom apply distinct combinations of regulatory, assessment, prescribing, and procurement processes. India’s large and diverse care system includes significant private-sector activity and uneven specialist access. Japan prioritizes detailed regulatory review and structured reimbursement, while South Korea combines advanced tertiary care with national coverage considerations. Mexico faces differences between public and private access. Russia’s environment is shaped by domestic policy, procurement, and healthcare-system constraints. The United States places substantial weight on specialty prescribing, payer policy, utilization management, and post-market safety evidence.

Priorities for Leaders: Build Evidence, Access, and Resilience Together

Industry leaders should define development programs around clinically meaningful endpoints, durable response, patient-reported outcomes, and clearly characterized subgroups. Evidence plans should anticipate regional assessment requirements and include real-world follow-up capable of informing persistence, safety, and treatment sequencing. Access strategies should account for affordability, distribution, administration settings, and diagnostic capacity rather than relying solely on clinical differentiation. Organizations should also establish responsible AI governance, strengthen supply continuity, engage clinicians and patient groups early, and maintain transparent pharmacovigilance throughout the product lifecycle.

Research Methodology: Evidence-Led and Geography-Specific Assessment

This executive summary uses a structured review framework focused on the IL-23 receptor antagonist therapeutic class. The approach synthesizes publicly available clinical, regulatory, policy, and healthcare-system evidence, then organizes findings by therapeutic trends, AI applications, region, economic or policy grouping, and country. Interpretations are limited to verifiable qualitative insights; no market estimates, market shares, forecasts, or company-specific claims are included. Because regulatory status, reimbursement, and clinical practice change over time, conclusions should be checked against current jurisdictional sources before operational decisions are made.

Conclusion: Targeted Biology Must Be Matched by System Readiness

IL-23 receptor antagonists are positioned within a broader move toward precise, durable management of immune-mediated disease. Their practical impact will depend not only on pharmacology and clinical evidence, but also on patient identification, specialist capacity, reimbursement, monitoring, supply reliability, and responsible use of digital tools. Leaders that connect robust evidence generation with regionally adapted access planning and accountable implementation will be better prepared to translate pathway-specific innovation into sustained patient benefit.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. IL-23 Receptor Antagonist Market, by Indication
7.1. Introduction
7.2. Crohn's Disease
7.3. Psoriasis
7.4. Psoriatic Arthritis
7.5. Ulcerative Colitis
8. IL-23 Receptor Antagonist Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous Infusion
8.3. Subcutaneous Injection
9. IL-23 Receptor Antagonist Market, by Therapy Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line
10. IL-23 Receptor Antagonist Market, by Patient Age Group
10.1. Introduction
10.2. Adults
10.3. Pediatrics
11. IL-23 Receptor Antagonist Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Retail Pharmacy
11.4. Specialty Pharmacy
12. IL-23 Receptor Antagonist Market, by Treatment Setting
12.1. Introduction
12.2. Hospital-based Treatment
12.3. Specialty Clinics / Dermatology Clinics
12.4. Homecare / Self-Administration
13. IL-23 Receptor Antagonist Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. Europe
13.4. North America
13.5. Africa
13.6. Latin America
13.7. Middle East
14. IL-23 Receptor Antagonist Market, by Group
14.1. Introduction
14.2. NATO
14.3. G7
14.4. European Union
14.5. BRICS
14.6. ASEAN
14.7. GCC
15. IL-23 Receptor Antagonist Market, by Country
15.1. Introduction
15.2. United States
15.3. China
15.4. Germany
15.5. Japan
15.6. India
15.7. United Kingdom
15.8. France
15.9. Canada
15.10. Italy
15.11. Australia
15.12. Brazil
15.13. Russia
15.14. South Korea
15.15. Mexico
15.16. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Johnson & Johnson Services, Inc.
17.3. Eli Lilly and Company
17.4. Sun Pharmaceutical Industries Limited
17.5. Almirall, S.A.
17.6. Amgen Inc.
17.7. Bio-Thera Solutions, Ltd.
17.8. Biocon Biologics Limited
17.9. Boehringer Ingelheim International GmbH
17.10. Celltrion, Inc.
17.11. China Medical System Holdings Limited
17.12. Huadong Medicine Co., Ltd.
17.13. Merck & Co., Inc.
17.14. Protagonist Therapeutics, Inc.
17.15. Qyuns Therapeutics Co., Ltd.
17.16. Samsung Bioepis Co., Ltd.
17.17. Sandoz International GmbH
17.18. Sanofi S.A.
17.19. Teva Pharmaceutical Industries Ltd.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global IL-23 Receptor Antagonist Market, Years Considered for the Study
FIGURE 2. Global IL-23 Receptor Antagonist Market, Research Design
FIGURE 3. Global IL-23 Receptor Antagonist Market, Research Framework
FIGURE 4. Global IL-23 Receptor Antagonist Market, Data Triangulation
FIGURE 5. Global IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
FIGURE 6. Global IL-23 Receptor Antagonist Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global IL-23 Receptor Antagonist Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global IL-23 Receptor Antagonist Market Size, by Therapy Line, 2025 vs 2032 (%)
FIGURE 11. Global IL-23 Receptor Antagonist Market Size, by Therapy Line, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2025 vs 2032 (%)
FIGURE 17. Global IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global IL-23 Receptor Antagonist Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global IL-23 Receptor Antagonist Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global IL-23 Receptor Antagonist Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global IL-23 Receptor Antagonist Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global IL-23 Receptor Antagonist Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global IL-23 Receptor Antagonist Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global IL-23 Receptor Antagonist Market Segmentation & Coverage
TABLE 2. Global IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 3. Global IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Crohn's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Crohn's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Crohn's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Psoriatic Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Psoriatic Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Psoriatic Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ulcerative Colitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ulcerative Colitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ulcerative Colitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 17. Global Intravenous Infusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Intravenous Infusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Intravenous Infusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 24. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Third Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Third Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Third Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 34. Global Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Pediatrics Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Pediatrics Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Pediatrics Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 41. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 51. Global Hospital-based Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Hospital-based Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Hospital-based Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Specialty Clinics / Dermatology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Specialty Clinics / Dermatology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Specialty Clinics / Dermatology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Homecare / Self-Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Homecare / Self-Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Homecare / Self-Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global IL-23 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific IL-23 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 68. Europe IL-23 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Europe IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 70. Europe IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 71. Europe IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 72. Europe IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 73. Europe IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. Europe IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 75. North America IL-23 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. North America IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 77. North America IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 78. North America IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 79. North America IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 80. North America IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 81. North America IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 82. Africa IL-23 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Africa IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 84. Africa IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 85. Africa IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 86. Africa IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 87. Africa IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Africa IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 89. Latin America IL-23 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Latin America IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 91. Latin America IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 92. Latin America IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 93. Latin America IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 94. Latin America IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. Latin America IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 96. Middle East IL-23 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Middle East IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 98. Middle East IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 99. Middle East IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 100. Middle East IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 101. Middle East IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. Middle East IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 103. Global IL-23 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. NATO IL-23 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. NATO IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 106. NATO IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 107. NATO IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 108. NATO IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 109. NATO IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 110. NATO IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 111. G7 IL-23 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. G7 IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 113. G7 IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 114. G7 IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 115. G7 IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 116. G7 IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. G7 IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 118. European Union IL-23 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. European Union IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 120. European Union IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 121. European Union IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 122. European Union IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 123. European Union IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. European Union IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 125. BRICS IL-23 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. BRICS IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 127. BRICS IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 128. BRICS IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 129. BRICS IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 130. BRICS IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. BRICS IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 132. ASEAN IL-23 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. ASEAN IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. ASEAN IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 135. ASEAN IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 136. ASEAN IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 137. ASEAN IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. ASEAN IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 139. GCC IL-23 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. GCC IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 141. GCC IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. GCC IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 143. GCC IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 144. GCC IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. GCC IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 146. Global IL-23 Receptor Antagonist Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. United States IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 148. United States IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 149. United States IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 150. United States IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 151. United States IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 152. United States IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. United States IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 154. China IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 155. China IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 156. China IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 157. China IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 158. China IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 159. China IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. China IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 161. Germany IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 162. Germany IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 163. Germany IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 164. Germany IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 165. Germany IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 166. Germany IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Germany IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 168. Japan IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 169. Japan IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. Japan IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. Japan IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 172. Japan IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 173. Japan IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. Japan IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 175. India IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 176. India IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. India IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 178. India IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 179. India IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 180. India IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. India IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 182. United Kingdom IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 183. United Kingdom IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 184. United Kingdom IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 185. United Kingdom IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 186. United Kingdom IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 187. United Kingdom IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. United Kingdom IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 189. France IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 190. France IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 191. France IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 192. France IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 193. France IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 194. France IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 195. France IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 196. Canada IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 197. Canada IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 198. Canada IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. Canada IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 200. Canada IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 201. Canada IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. Canada IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 203. Italy IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 204. Italy IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 205. Italy IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 206. Italy IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 207. Italy IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 208. Italy IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. Italy IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 210. Australia IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 211. Australia IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 212. Australia IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 213. Australia IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 214. Australia IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 215. Australia IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. Australia IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 217. Brazil IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 218. Brazil IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 219. Brazil IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 220. Brazil IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 221. Brazil IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 222. Brazil IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. Brazil IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 224. Russia IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 225. Russia IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 226. Russia IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 227. Russia IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 228. Russia IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 229. Russia IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. Russia IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 231. South Korea IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 232. South Korea IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 233. South Korea IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 234. South Korea IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 235. South Korea IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 236. South Korea IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. South Korea IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 238. Mexico IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 239. Mexico IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. Mexico IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 241. Mexico IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 242. Mexico IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 243. Mexico IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. Mexico IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 245. Spain IL-23 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 246. Spain IL-23 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 247. Spain IL-23 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 248. Spain IL-23 Receptor Antagonist Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 249. Spain IL-23 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 250. Spain IL-23 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. Spain IL-23 Receptor Antagonist Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 252. Global IL-23 Receptor Antagonist Market Share, by Key Player, 2025
TABLE 253. Global IL-23 Receptor Antagonist Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Limited
  • Almirall, S.A.
  • Amgen Inc.
  • Bio-Thera Solutions, Ltd.
  • Biocon Biologics Limited
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • China Medical System Holdings Limited
  • Huadong Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Protagonist Therapeutics, Inc.
  • Qyuns Therapeutics Co., Ltd.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Related Topics

Related Reports

IL-12 Receptor Antagonist Market - Global Forecast 2026-2032 - Product Image

IL-12 Receptor Antagonist Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
IL-1 Receptor Antagonist Market - Global Forecast 2026-2032 - Product Image

IL-1 Receptor Antagonist Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors - Product Image

Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors

  • Report
  • Global
From
Arcalyst (rilonacept) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Arcalyst (rilonacept) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Monoclonal Antibodies - Competitive Landscape, 2026 - Product Image

Monoclonal Antibodies - Competitive Landscape, 2026

  • Report
  • 450 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.